Radioactive bullet targets Hard-to-Treat prostate cancer
Disease control
Recruiting now
This study tests a new drug called INR102, which delivers radiation directly to prostate cancer cells. It is for men with a specific type of advanced prostate cancer that has spread and no longer responds to hormone therapy. The trial will check safety, how the drug moves through…
Phase: PHASE1, PHASE2 • Sponsor: Yunhe Pharmaceutical (Tianjin) Co., Ltd • Aim: Disease control
Last updated Jun 27, 2026 08:08 UTC